Bevacizumab biosimilar(Shanghai Henlius)

美国时间6月16 - 19日，2025美国生物技术大会暨展览会（2025 BIO International Convention, “BIO 2025”）在美国麻省波士顿会展中心（Boston Convention & Exhibition Center）举行。复宏汉霖连续第七年再次亮相此次大会，在1885展台为参会嘉宾带来精彩展示，吸引了众多参会者及组织机构前来参观交流。展会期间，复宏汉霖高效开展了约130场会面，聚焦创新产品、前沿技术平台及肿瘤免疫疗法等领域的合作机遇与潜在合作伙伴展开深入交流。左右滑动查看更多复宏汉霖高级副总裁兼首席商务发展官曹平女士在BIO主题演讲中强调：公司成立以来始终践行为患者提供高质量且可负担的创新药物的使命，全球累计惠及患者超80万例，实现从研发到商业化的价值闭环。复宏汉霖首席技术官、高级副总裁许圣昌博士聚焦复宏汉霖在AI辅助药物开发领域的突破性进展进行了介绍，印证了公司"创新-可及"双引擎发展路径的国际竞争力。此外，在公司协办的“BlOCHINA Global Forum 2025@Boston”中国生物药国际化论坛上，曹平女士与公司总裁黄玮女士携手全球合作伙伴Accord、Dr.Reddy's、Palleon、Organon、Sermonix，分享与中国生物制药企业合作的核心驱动力和战略考量，全面展示了公司的国际化合作布局，引发业界的高度聚焦与广泛赞誉，进一步增强了公司在全球生物医药市场的影响。左右滑动查看更多复宏汉霖以患者需求为根基，以创新为引擎，以全球化为驱动，依托前沿的生产与质量体系和卓越的商业化运营能力，致力于为全球患者提供可负担的高品质生物药。公司就汉曲优®（美国商品名：HERCESSI™，欧洲商品名：Zercepac®）、H药 汉斯状®（斯鲁利单抗，欧洲商品名：Hetronifly®）、汉利康®、HLX11、HLX14、HLX15等多个产品，携手Accord、Abbott、Dr.Reddy’s、Eurofarma、KGbio、Sandoz和Organon等国际一流的生物制药企业拓展全球市场，授权区域全面覆盖欧美主流生物药市场和众多新兴市场。汉曲优®是在中美欧三地皆获批的“中国籍”单抗生物类似药，现已在超过50个国家和地区获批上市，其商业化供货网络已覆盖中国、东南亚、北美、欧洲、中东及拉丁美洲等地区，惠及超过25万名患者。公司另一款抗肿瘤核心产品H药 汉斯状®是全球首个获批用于一线治疗小细胞肺癌（SCLC）的抗PD-1单抗，已在中国、欧洲及东南亚等30余个国家和地区获批上市。同时，H药治疗SCLC也已获得美国FDA、欧盟EC、瑞士Swissmedic的孤儿药资格认定，并获韩国MFDS授予ES-SCLC孤儿药资格，有望惠及全球更广泛的肿瘤患者群体。与此同时，公司高效推进创新管线产品的临床进展，创新型抗HER2单抗HLX22的国际多中心III期研究同步于中国、澳大利亚、欧盟、日本、美国、南美洲等国家和地区开展。潜在同类首创/最优产品HLX43（PD-L1 ADC）的国际多中心II期临床研究于中国完成首例受试者给药，是全球首个进入临床II期的靶向PD-L1的ADC产品。未来，复宏汉霖将继续携手全球合作伙伴，通过创新与合作，为全球患者带来更多优质、可负担的治疗选择。关于复宏汉霖复宏汉霖（2696.HK）是一家国际化的创新生物制药公司，致力于为全球患者提供可负担的高品质生物药，产品覆盖肿瘤、自身免疫疾病、眼科疾病等领域，已有6款产品在中国获批上市，4款产品在国际获批上市，5个上市申请分别获中国药监局、美国FDA和欧盟EMA受理。自2010年成立以来，复宏汉霖已建成一体化生物制药平台，高效及创新的自主核心能力贯穿研发、生产及商业运营全产业链。公司已建立完善高效的全球创新中心，按照国际药品生产质量管理规范（GMP）标准进行生产和质量管控，不断夯实一体化综合生产平台，其中，公司商业化生产基地已相继获得中国、欧盟和美国GMP认证。复宏汉霖前瞻性布局了一个多元化、高质量的产品管线，涵盖约50个分子，并全面推进基于自有抗PD-1单抗H药汉斯状®的肿瘤免疫联合疗法。截至目前，公司已获批上市产品包括国内首个生物类似药汉利康®（利妥昔单抗）、自主研发的中美欧三地获批单抗生物类似药汉曲优®（曲妥珠单抗，美国商品名：HERCESSI™，欧洲商品名：Zercepac®）、汉达远®（阿达木单抗）、汉贝泰®（贝伐珠单抗）、全球首个获批一线治疗小细胞肺癌的抗PD-1单抗汉斯状®（斯鲁利单抗，欧洲商品名：Hetronifly®）以及汉奈佳®（奈拉替尼）。公司亦同步就19个产品在全球范围内开展30多项临床试验，对外授权全面覆盖欧美主流生物药市场和众多新兴市场。Henlius Shines at 2025 BIO International Convention, Showcasing Its Innovative AchievementsFrom June 16-19, 2025, the 2025 BIO International Convention (“BIO 2025”) was held at the Boston Convention & Exhibition Center in Boston, Massachusetts, USA. Marking its seventh consecutive year at the conference, Henlius showcased a wide range of innovative research and development accomplishments, attracting significant attention from numerous attendees and organizations. During the conference, Henlius held around 130 in-depth meetings, driving exchanges on collaboration opportunities for in-licensing, research collaboration, or commercial right out-licensing.  Ping Cao, Henlius SVP and Chief Business Development Officer, emphasized in her BIO keynote: Henlius has delivered on its mission to provide high-quality and affordable biologics since inception, benefiting over 800,000 patients globally while achieving end-to-end value integration from R&D to commercialization. Simon Hsu, CTO and SVP of Henlius, highlighted breakthroughs in AI-driven drug development, demonstrating how Henlius' double engines of innovation and accessibility fuel its global competitiveness. Additionally, at the 'BIO CHINA Global Forum 2025@Boston' co-hosted by Henlius, the company's executives engaged in in-depth discussions with global partners Accord, Dr. Reddy's, Palleon, Organon, and Sermonix on strategic drivers for global partnerships with Chinese biopharma, showcasing our international footprint. The dialogue sparked significant industry attention and further amplified the company's global influence in the biologics market. Henlius anchors its strategy in unmet patient needs, powers progress through continuous innovation and advances its global presence with manufacturing and quality systems, as well as commercialization capabilities, delievering the goals of providing innovative and affordable biologics for global patients. The company has expanded its global market presence with several products, including HANQUYOU, HANSIZHUANG, HANLIKANG, HLX11, HLX14, and HLX15, in collaboration with renowned international biopharmaceutical companies such as Accord, Abbott, Dr.Reddy’s, Eurofarma, KGbio, Sandoz and Organon. It has achieved comprehensive coverage in the mainstream biopharmaceutical markets of Europe, the United States, and numerous emerging markets, contributing to the global development of China's biopharmaceutical innovation. Henlius’ self-developed and manufactured trastuzumab biosimilar HANQUYOU (trade name: HERCESSI™ in U.S. and Zercepac® in Europe) is a China-developed mAb biosimilar approved in China, Europe, and U.S. It has been approved in over 50 countries and regions, covering China, Southeast Asia, North America, the EU, Middle East, and Latin America, benefiting over 250,000 patients. Additionally, the company prides itself on its HANSIZHUANG (serplulimab, trade name: Hetronifly ® in Europe), the world's first anti-PD-1 mAb for the first-line treatment of small cell lung cancer (SCLC), and it has been approved in more than 30 countries and regions, including China, the EU, and Southeast Asia. To date, Orphan Drug Designation (ODD) granted to HANSIZHUANG for the treatment of SCLC by U.S. FDA, EC, and Swissmedic, and for Extensive-Stage SCLC (ES-SCLC) by Korea MFDS. Meanwhile, the company is efficiently advancing the clinical progress of its innovative product portfolio. The phase 3 international multicentre clinical trails of Henlius' novel anti-HER2 mAb, HLX22, is being conducted simultaneously across China, Australia, the European Union, Japan, the United States, South America, and other countries and regions. Recently, the first subject has been dosed for a phase 2 international muticenter clinical trial of HLX43（PD-L1 ADC）, another company’s potential first/best-in-class products. At present, HLX43 is the first PD-L1 ADC progressed to phase 2 clinical trial development globally. Looking forward, Henlius will continue to collaborate closely with global partners, leveraging innovation and cooperation, to deliver more high-quality, affordable treatment options to patients worldwide.About HenliusHenlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 4 have been approved for marketing in overseas markets, and 5 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company's launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, and HANNAIJIA (neratinib). What’s more, Henlius has conducted over 30 clinical studies for 19 products, expanding its presence in major markets as well as emerging markets.联系方式媒体：PR@Henlius.com投资者：IR@Henlius.com喜欢本文内容点击下方按钮·分享 ·收藏 ·点赞 ·在看